Focal adhesion complex (FAC) (FAC)

Focal adhesion complexes (FACs) are large, dynamic multi-protein assemblies that function as the primary physical and signaling interface between the intracellular actin cytoskeleton and the extracellular matrix (ECM) [1]. These complexes are nucleated by transmembrane integrin receptors, which, upon binding to ECM ligands, recruit a vast network of scaffolding proteins (e.g., talin, vinculin, paxillin) and signaling enzymes, most notably Focal Adhesion Kinase (FAK) and Src family kinases [2, 3]. Biologically, FACs are essential for mechanotransduction, converting physical environmental cues into biochemical signals that regulate fundamental processes such as cell survival, proliferation, and directed migration [1, 3]. In various diseases, particularly solid tumors, the components of the focal adhesion complex are frequently overexpressed or hyperactivated, promoting an invasive phenotype, epithelial-mesenchymal transition (EMT), and resistance to chemotherapy-induced apoptosis [4]. Consequently, the FAC has become a significant focus for therapeutic intervention, with drug development primarily targeting its enzymatic drivers like FAK and Src, or disrupting integrin-mediated adhesion [2, 4]. While targeting these complexes offers potent anti-metastatic potential, challenges include managing toxicities related to the ubiquitous role of focal adhesions in normal tissue maintenance, vascular stability, and wound healing [5].

Other names

Focal adhesionCell-matrix adhesionIntegrin-mediated adhesion complexAdhesion plaque

Inhibition of the catalytic activity of key enzymatic components (e.g., Focal Adhesion Kinase, Src) or competitive inhibition of integrin-ligand binding to attenuate downstream pro-survival and pro-migratory signaling pathways such as PI3K/Akt and Ras/MAPK [2, 4].